bioRxivMicrobiology
A Clostridia-rich microbiota contributes to increased excretion of bile acids in diarrhea-predominant irritable bowel syndrome
L. Zhao, W. Yang, Y. Chen, F. Huang, L. Lu, C. Lin, T. Huang, Z. Ning, L. Zhai, L. L. Zhong, W. Lam, Z. Yang, X. Zhang, C. Cheng, L. Han, Q. Qiu, X. Shang, R. Huang, Z. Ren, D. Chen, S. Sun, H. El-Nezami, A. Lu, X. Fang, W. Jia, Z. Bian
Abstract
ObjectiveAn excess of fecal bile acids (BAs) is thought to be one of the mechanisms for diarrhea-predominant irritable bowel syndrome (IBS-D). However, the factors causing excessive BA excretion remains unclear. Given the importance of gut microbiota in BA metabolism, we hypothesized that gut dysbiosis might contribute to excessive BA excretion in IBS-D.\n\nDesignMetabolomic and metagenomic analyses were performed of specimens from 290 IBS-D patients and 89 healthy volunteers. By transplanting human microbiota and manipulating specific microbiome species in mice, the effects of microbiota on host BA metabolism were assessed at metabolic, genetic and protein levels. Effects of individual and mixed BAs on enterohepatic feedback pathways were also tested in vitro and in vivo.\n\nResultsTotal fecal BAs were excessively excreted in 24.5% of IBS-D patients. Their fecal metagenomes showed increased abundances of Clostridia and BA-transforming genes (hdhA and bais). The increases of Clostridia bacteria (e.g. C. scindens) were positively associated with the levels of fecal BAs and serum 7-hydroxy-4-cholesten-3-one (C4), while being negatively correlated with serum fibroblast growth factor 19 (FGF19). Both Clostridia-rich human microbiota and C. scindens enhanced levels of serum C4 and hepatic conjugated BAs in mice recipients and reduced ileal FGF19 expression. Inhibition of Clostridium species by vancomycin yielded opposite findings. Clostridia-derived BAs (e.g. conjugated and free ursodeoxycholic acid) significantly suppressed intestinal FGF19 expression.\n\nConclusionThe Clostridia-rich microbiota contributes to excessive BA excretion in IBS-D patients. This study provided the basis for more precise clinical diagnosis and management for IBS-D.
- organism: human
- assay: metagenomics
- assay: metabolomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A microbial derived bile acid acts as GPBAR1 agonist and RORγt inverse agonist and reverses inflammation in inflammatory bowel disease
M. Biagioli, C. Di Giorgio, … S. Fiorucci·bioRxiv·Apr 8, 2024
- Host-derived bile acids drive dysbiosis by selecting bile-resistant epimerizing bacteria in inflammatory bowel disease
Maximilian Baumgartner, Franziska Schnaufer, … Clarissa Campbell·bioRxiv·Jun 19, 2026
- Phenethylamine-producing gut bacteria induces diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis
L. Zhai, C. Huang, … Z.-x. Bian·bioRxiv·Mar 5, 2022
- Personalized modeling of the human gut microbiome reveals distinct bile acid deconjugation and biotransformation potential in healthy and IBD individuals
Almut Heinken, Dmitry A. Ravcheev, … Ines Thiele·bioRxiv·Dec 4, 2017
- Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome
A. Pearl, H. Bootz, … N. Yissachar·bioRxiv·Aug 15, 2021
- Enhancing Recovery from Gut Microbiome Dysbiosis and Alleviating DSS-Induced Colitis in Mice with a Consortium of Rare Short-Chain Fatty Acid-Producing Bacteria